Thursday, May 07, 2015
When the dust settled last May on years of litigation over bleeding risks from the blockbuster anticoagulant Pradaxa, German manufacturer Boehringer Ingelheim had agreed to pay $650 million to compensate around 4,000 patients and surviving family members.
The problem with the settlement, legal experts pointed out, was that Pradaxa was still being prescribed to millions of new patients with little warning of the potential for internal bleeding. And, those hospitalized after May 2014 would not receive compensation.
Not fair, said a group of leading drug injury law firms, who have commenced plans to start new Pradaxa litigation in a different court this year.